1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6EB851332335110D7652578570029BEB0
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/cardiovascular-products-successful-market-entry-differentiation-and-pricing?opendocument
18
19opendocument
2034.226.234.20
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Product Launch Market Entry: Metabolic and Cardiovascular Diseases

Product Factors that Shape a Successful Cardiovascular Market Entry: Differentiation, Pricing and Therapy Benefits

ID: 5127


Features:

21 Info Graphics

15 Data Graphics

75+ Metrics

18 Narratives


Pages/Slides: 61


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Product Factors that Shape a Successful Cardiovascular Market Entry: Differentiation, Pricing and Therapy Benefits"

STUDY OVERVIEW

As new products enter the highly competitive and crowded cardiovascular market, it is important for biopharmaceutical companies to differentiate their product during launch. Factors that shape a new cardiovascular product's market entry include how well the product is differentiated from existing therapies, product pricing and its benefits - ease of use, fewer side effects, etc.

Best Practices, LLC undertook a benchmarking study to highlight the effectiveness of different launch strategies around differentiation, pricing and product benefits. The study also analyses issues surrounding a product's safety and efficacy profile to establish how much more effective or safe a new cardiovascular product needs to be for a blockbuster launch. Launch leaders can use insights from this research to inform their market entry strategies for new cardiovascular products.

KEY TOPICS

  • Summary of business issue, key insights, findings and lessons learned
  • Winning on differentiated product positioning
  • Articulating benefits that shape positive market perception
  • New product pricing strategy
  • Rating the effectiveness of efficacy dimensions
  • Rating different safety dimensions


SAMPLE METRICS
  • Effectiveness rating for different positioning strategies
  • Effectiveness rating of various cardiovascular product benefits for differentiation
  • Cardiovascular product differentiation factors that best permit superior pricing
  • Minimum level of superior efficacy needed to charge more in crowded marketplace
  • Best pricing strategy when entering market with generics competition
  • Minimum level of superior efficacy required to charge more than generics
  • How much more effective than leading treatment does new product need to win physician trial
  • How much more effective than leading treatment does new product need to win payer support
  • Rating different safety dimensions that compel physician trial

SAMPLE KEY FINDING
  • Identify A Differentiated Target Patient Population & Help Physicians Correctly Identify Right Target Patients: A clearly defined target patient population or subpopulation has high impact on successful market entry and potential product differentiation. Moreover, it is a launch factor that is frequently missed or executed poorly. Target patient sub-population is also a marketing-sensitive factor and is a cornerstone of market-entry success.


METHODOLOGY

The research employed a data gathering approach that gleaned quantitative data from 44 executives and managers from 38 leading companies in pharmaceutical, biotechnology and medical device industries. In addition, six executives participated in in-depth interviews.


Industries Profiled:
Pharmaceutical; Biotech; Medical Device; Health Care; Chemical; Manufacturing; Consumer Products; Diagnostic; Media


Companies Profiled:
Abbott Laboratories; Amgen; Actelion; AstraZeneca; GlaxoSmithKline; Bristol-Myers Squibb; Roche; Lilly; Novartis; Merck; Genentech; MedImmune; Bayer; Cephalon; Inc.; Teva Neuroscience; Novo Nordisk; Amylin; Laboratorios Deramtologicos Darier; IDS Canada; UCB Pharma; Quintiles; Ther-Rx; ProCaps Laboratories; Baxter Healthcare; Synapse biomedical; Talecris; Eisai; Shire; Takeda Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.